Treatment of HBsAg-positive chronic active hepatitis with human fibroblast interferon


From the Professorial Medical Unit, Southampton General Hospital, and Searle Research Laboratories, High Wycombe, Bucks.

SUMMARY Two patients with HBsAg positive chronic active hepatitis have been treated with human fibroblast interferon 10^7 units daily for two weeks. Before treatment, both patients had high levels of hepatitis B surface antigen, core antibody, and DNA-binding antibody in the blood and one patient had a fourfold rise in serum AST. During treatment there was a striking fall in the core antibody titre and also in the DNA-binding antibody, which has been maintained for several months subsequently; in one patient the initially high AST level fell to normal. No significant adverse effects occurred, and these observations should encourage further trials of fibroblast interferon in hepatitis B.

Chronic hepatitis B infection is a major clinical problem, but there is no established method of treatment for the liver disease or for the elimination of the carrier state.

Two recent reports have demonstrated modification of certain markers of chronic hepatitis B infection in man by the administration of human interferon. Greenberg et al. (1976) treated four HBsAg-positive chronic active hepatitis patients with human leucocyte interferon and Desmyter et al. (1976) used human fibroblast interferon to treat another patient. Among the changes in the markers of hepatitis B infection which they observed were a fall in the Dane particle core antigen and DNA polymerase activity, elimination of the e antigen, and depression of the concentration of hepatitis B core antigen in the liver. One or more of these changes was observed if the interferon was given for a period of 10 days to two weeks, but was transient, and more prolonged treatment was necessary to modify the titre of HBsAg. Treatment of chimpanzees chronically infected with hepatitis B virus using fibroblast interferon (Desmyter et al., 1976) or an interferon inducer (Purcell et al., 1976) has produced similar results.

We here report the effect of administering human fibroblast interferon (HFIF) to two patients with HBsAg-positive chronic active hepatitis.

Received for publication 2 September 1977

Methods

Two patients with HBsAg-positive chronic active hepatitis were treated in hospital with HFIF 10^7 units daily by subcutaneous or intramuscular injection for two weeks. The human fibroblast interferon was produced from a newly established line of human fetal lung fibroblast cells by induction with poly-I-C and superinduction with actinomycin D and cycloheximide (Sehgal et al., 1976). It was concentrated by ultrafiltration and purified by precipitation with ammonium sulphate and chromatography on concanavalin A sepharose, giving a final activity of 10^6 units interferon/mg protein and a concentration of 10^7 units/ml. Circulating interferon levels were assayed serially during treatment by the 50% inhibition of cytopathic effect of Sindbis virus in Vero cells (Chisholm and Cartwright, 1975).

Serial specimens of blood were taken for assays of markers of hepatitis B infection, immunological studies, tests of liver function, including aspartate aminotransferase (AST), haemoglobin, white blood cell (wbc) and platelet counts, and tests of renal function. The hepatitis B markers measured on coded specimens of serum included HBsAg, HBsAb, anti-HBc, e antigen and antibody, and the presence of Dane particles. HBsAg was measured by passive haemagglutination (Hepatetest Wellcome Reagents Ltd.) and radioimmunoassay (Ausria II—Abbott
Laboratories). HBsAb was measured by radioimmunoassay (Ausab—Abbott Laboratories). Anti-HBc titres were measured by complement fixation in doubling dilutions in microtitre plates. The HBCAg was extracted from post-mortem human liver from an immunosuppressed patient (kindly provided by Mr B. Cohen of the PHLS Laboratories, Colindale). The reaction was confirmed by counter-electrophoresis in both patients, and aggregates of HB core particles and antibody were observed in the excised precipitin line by electron microscopy with negative staining. e antigen and antibody were detected by immunodiffusion in agar (Nielsen et al., 1974) using reference sera kindly provided by Dr Nielsen. Serum specimens were examined for Dane particles by electron microscopy with negative staining as described previously (Wright, 1970) using a Phillips 300 electron microscope. Double-stranded DNA-binding antibodies, which are known to be raised in acute and chronic hepatitis B (Jain et al., 1976) were measured by a modification of the Farr technique (Carr et al., 1969). Binding was assayed at 4°C using calf thymus DNA-labelled with tritiated actinomycin D; the normal range in our laboratory is 5—11%.

Results

Patient 1, J. H., a 57 year old male, was found to have a finely nodular enlarged liver at laparotomy for a duodenal ulcer in January 1976. Liver biopsy showed typical features of chronic aggressive hepatitis with early cirrhosis. HBsAg in serum was positive, HBsAb negative, and e antigen and antibody negative. Serum Dane particles were scanty. Liver function tests were normal, apart from a slight rise in the AST. The patient remained well, with persistently positive HBsAg and mildly raised AST from January to November 1976, when repeat liver biopsy was essentially unchanged.

Patient 2, D. P., a 22 year old drug addict, contracted mild hepatitis B in June 1975. Hepatosplenomegaly with raised AST persisted, and in December 1975 liver biopsy showed features of chronic aggressive hepatitis. HBsAg and e antigen were positive. Repeat liver biopsy in October 1976 confirmed the diagnosis of chronic active hepatitis. HBsAg remained positive, but e antigen had become negative.

On 8 December 1976, both patients were admitted for treatment with interferon, at which time both were asymptomatic but had hepatomegaly. Neither reacted to a test dose of 50 000 U HFIF in 0·1 ml tissue culture medium intradermally. Thereafter, patient 1 was given 10⁷ U HFIF in 1 ml subcutaneously to alternate upper arms daily for 14 days, and plasma levels up to 10 units per ml interferon were achieved. The patient tolerated the injections well, with only slight local tenderness and erythema after 24 hours, which decreased during the course of treatment.

In patient 2, a 3-cm indurated area developed at the site of the first injection of 10⁷ units of HFIF subcutaneously, but subsequent intramuscular injections of the same dose into the buttocks daily for 14 days produced no local reaction, and circulating interferon levels up to 100 units per ml were achieved. Neither patient had pyrexia or tachycardia, and haemoglobin, white blood cells and platelet counts were normal throughout.

In patient 1, the liver function tests remained normal, but in patient 2 the AST rose from 140 units before treatment to 183 units on day 6, and subsequently fell below pre-treatment levels (Figure). In both patients there was a marked fall in anti-HBc during treatment, and the titre has remained low for four months following treatment (Figure). HBsAg titres fluctuated transiently during treatment, e antigen and antibody and HBsAb have remained persistently negative, and in both patients only occasional Dane particles have been observed in the serum throughout. In both patients DNA-binding antibodies were raised before treatment to the range expected in chronic active hepatitis, but fell to normal during treatment, where they have since remained (Figure).

Discussion

Both patients with HBsAg-positive chronic active hepatitis reported here showed a marked fall in the titre of antibody to hepatitis core antigen during a two-week course of treatment with human fibroblast interferon. This confirms earlier reports of the modification of hepatitis B markers by interferon in both man (Desmyter et al., 1976; Greenberg et al., 1976) and the chimpanzee (Desmyter et al., 1976; Purcell et al., 1976). Greenberg et al. (1976) showed depression of DNA polymerase activity, a decrease in Dane particle-associated DNA, and disappearance of the e antigen after treatment with interferon. They also observed a fall in the titre of HBCAg. Prolonged treatment was necessary to alter the HBsAg titre significantly. We did not measure DNA polymerase activity, but since this correlates well with the presence of the e antigen, which was negative in our patients, and Dane particles in the serum (Nordenfelt and Kjellen, 1975), which were sparse, it is likely that the DNA polymerase titre was low or absent.

The marked fall in anti-HBc, as well as DNA-binding antibodies, in our patients following
Treatment of HBsAg-positive chronic active hepatitis with human fibroblast interferon

Figure  The effect of treatment with human fibroblast interferon 10⁷ units daily on titres of HBsAg, anti-core antibody and DNA-binding antibody, and on AST levels in two patients with chronic active hepatitis.

Interferon treatment is intriguing. Interferon may release hepatitis B core antigen from the liver, which becomes complexed with anti-HBc, producing a fall in titre. The observations of Desmyter et al. (1976) on the decrease in core antigen in the liver after treatment with interferon favours this possibility, as does the fall in titre of HB core antigen in serum reported by Greenberg et al. (1976).

The fall in DNA-binding antibody in the serum may have a similar explanation. Free circulating Dane particle-associated DNA has been demonstrated in the serum in hepatitis B infection (Hung et al., 1975). Interferon treatment, by releasing specific Dane particle-associated DNA or hepatocyte nuclear DNA, may react with antibody which we are detecting using calf thymus DNA to produce the fall in binding antibody observed in both patients. Alternatively, interferon, by stopping viral replication in the liver, may reduce the production of core antigen and its associated DNA, causing a fall in the titre of anti-HBc and DNA-binding antibodies. This is favoured by the persistence of low titres for some months after treatment and the fall in AST level in one patient.

The titres of HBsAg did not fall significantly during treatment, which is not surprising as the studies of Greenberg et al. (1976) suggest that a more prolonged course of treatment is necessary before any effect is observed.

We suggest that these results should encourage further trials of interferon in hepatitis B, using more prolonged courses of treatment, and that human fibroblast interferon appears to be well tolerated in the dosage used. In particular, the haematological depression which may occur with leucocyte interferon (Greenberg et al., 1976) was not observed.

We wish to thank Dr A. J. Hale and Dr G. R. Venning for support and encouragement, Dr R. Dathan and Mr J. Webster for referring patients for treatment, and Mrs G. Le Du for laboratory assistance. N. K. G. is in receipt of a Commonwealth Medical Fellowship.

References


antigen-positive patients with acute and chronic liver disease. Lancet, 2, 913-915.


Treatment of HBsAg-positive chronic active hepatitis with human fibroblast interferon.

J G Kingham, N K Ganguly, Z D Shaari, R Mendelson, M J McGuire, S J Holgate, T Cartwright, G M Scott, B M Richards and R Wright

doi: 10.1136/gut.19.2.91

Updated information and services can be found at:
http://gut.bmj.com/content/19/2/91

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/